Esperion Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Esperion Therapeutics, Inc. (ESPR), sourced directly from SEC EDGAR and updated as new filings are accepted.
Quick Answer
Are ESPR insiders buying or selling?
Esperion Therapeutics, Inc. insiders reported 35 open-market buys ($56.0M) and 75 sells ($11.2M) across 110 Form 4 filings — a net buying position of $44.8M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 18, 2026)
Insider sentiment
Net buyingNet insider flow of $44.8M in net buying.
Recent ESPR insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Benjamin Looker | Chief Legal Officer | Sale | 11.8K | $3.16 | $37.3K |
| Jun 18, 2026 | Sheldon L. Koenig | President and CEO | Sale | 53.6K | $3.16 | $169.1K |
| Jun 18, 2026 | Benjamin Halladay | Chief Financial Officer | Sale | 10.8K | $3.16 | $34.0K |
| Mar 18, 2026 | Benjamin Looker | Chief Legal Officer | Sale | 5.7K | $2.70 | $15.4K |
| Mar 18, 2026 | Sheldon L. Koenig | President and CEO | Sale | 25.6K | $2.72 | $69.5K |
| Mar 18, 2026 | Benjamin Halladay | Chief Financial Officer | Sale | 6.4K | $2.71 | $17.4K |
| Jan 21, 2026 | Benjamin Looker | General Counsel | Sale | 1.7K | $2.88 | $4.9K |
| Dec 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 48.2K | $3.67 | $177.2K |
| Dec 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.3K | $3.67 | $26.9K |
| Dec 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.5K | $3.67 | $23.9K |
| Oct 20, 2025 | Benjamin Looker | General Counsel | Sale | 1.2K | $2.62 | $3.3K |
| Sep 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.3K | $2.80 | $17.6K |
| Sep 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 28.4K | $2.79 | $79.3K |
| Sep 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.0K | $2.81 | $19.8K |
| Jul 18, 2025 | Benjamin Looker | General Counsel | Sale | 1.3K | $1.13 | $1.5K |
| Jul 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 11 | $1.12 | $12.27 |
| Jun 18, 2025 | Benjamin Looker | General Counsel | Sale | 6.4K | $1.15 | $7.4K |
| Jun 18, 2025 | Sheldon L. Koenig | President and CEO | Sale | 30.5K | $1.11 | $33.8K |
| Jun 18, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 7.2K | $1.15 | $8.3K |
| Apr 21, 2025 | Eric Warren | Chief Commercial Officer | Sale | 108 | $0.98 | $105.62 |
| Apr 21, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 8 | $0.96 | $7.71 |
| Mar 19, 2025 | Benjamin Halladay | Chief Financial Officer | Sale | 3.5K | $1.48 | $5.2K |
| Mar 19, 2025 | Eric Warren | Chief Commercial Officer | Sale | 2.4K | $1.49 | $3.6K |
| Mar 19, 2025 | Sheldon L. Koenig | President and CEO | Sale | 13.0K | $1.50 | $19.6K |
| Feb 20, 2025 | Eric Warren | Chief Commercial Officer | Sale | 239 | $1.87 | $446.45 |
Showing the 25 most recent of 110 Form 4 filings for Esperion Therapeutics, Inc..
Most active ESPR insiders
- Eric Warren27 filings
- V N Biotech Target19 filings
- Sheldon L. Koenig15 filings
- Benjamin Halladay11 filings
- Benjamin Looker10 filings
Ask anything about ESPR insider activity
Use Trabud's AI agent to query Esperion Therapeutics, Inc.'s Form 4 history in plain English — "Show me ESPR CEO purchases this year" or compare it against any other ticker.
Open the AI agentESPR insider trading FAQ
Are Esperion Therapeutics, Inc. insiders buying or selling?
Across 110 SEC Form 4 filings, Esperion Therapeutics, Inc. (ESPR) insiders reported 35 open-market purchases totaling $56.0M and 75 sales totaling $11.2M. That is a net buying position of $44.8M.
How many insiders trade ESPR stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Esperion Therapeutics, Inc.. The most recent filing was accepted on Jun 18, 2026.
Where does Trabud get ESPR insider trading data?
All ESPR insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.